Key Takeaways
- • Canadian Cancer Society commits up to $10 million to the Cancer Breakthrough Fund, matching the Terry Fox Foundation's commitment and marking the first time either national Canadian cancer research body has entered venture capital funding of commercial ventures.
- • Cancer Breakthrough Fund has raised over $30 million of its $50 million target since announcement one year ago, with additional investors including Rally Assets, Boann Social Impact, and the Northpine Foundation (backed by early Shopify investor John Phillips and his wife Cathy).
- • Lumira Ventures, one of Canada's largest life sciences VC firms, manages the fund and plans 13 investments with minimum 25% allocation to early-stage cancer treatment developers; remaining capital will co-invest alongside Lumira's separate US$200 million life sciences fund targeting 40% cancer sector allocation.
- • Strategy mirrors successful U.S. philanthropic models including the Cystic Fibrosis Foundation, American Cancer Society's BrightEdge fund, and the Juvenile Diabetes Research Foundation's T1D fund, representing a shift toward blending philanthropic and venture capital approaches in biomedical funding.
Summary
The Canadian Cancer Society and Terry Fox Foundation have entered the venture capital space through the Cancer Breakthrough Fund, signaling a strategic pivot by Canada's largest cancer research organizations toward commercial investment in treatment development. The 88-year-old Canadian Cancer Society has committed up to $10 million to the fund, matching the Terry Fox Foundation's pledge. This represents the first time either organization has committed capital to fund commercial cancer treatment ventures, departing from their traditional roles as basic research funders.
The Cancer Breakthrough Fund, managed by Lumira Ventures, has secured over $30 million in commitments against a $50 million target since its announcement slightly over one year ago and is preparing to deploy its first investments. Additional institutional backing comes from social impact investors Rally Assets and Boann Social Impact, as well as the Northpine Foundation, which was established by John Phillips, an early Shopify backer, and his wife Cathy. According to Peter van der Velden, executive chairman of Lumira Ventures, the fund expects to complete its fundraising and close its initial tranche soon.
The investment strategy allocates at least 25% of fund proceeds to early-stage cancer treatment developers, with remaining capital deployed through co-investment arrangements alongside Lumira's separate life sciences fund, which is currently raising US$200 million for Canadian and U.S. life sciences companies. The larger Lumira fund targets 40% of its total allocation to cancer-focused companies. The Cancer Breakthrough Fund is structured to make approximately 13 total investments across both early and more advanced development stages.
This philanthropic venture capital model mirrors successful precedents in the U.S., including the Cystic Fibrosis Foundation's venture initiatives, the American Cancer Society's BrightEdge fund, and the Juvenile Diabetes Research Foundation's T1D fund. The approach represents an evolution in how major disease-focused nonprofits are mobilizing capital to accelerate commercial development of breakthrough treatments, combining nonprofit mission focus with venture capital's operational and financial discipline.
The Cancer Breakthrough Fund, managed by Lumira Ventures, has secured over $30 million in commitments against a $50 million target since its announcement slightly over one year ago and is preparing to deploy its first investments. Additional institutional backing comes from social impact investors Rally Assets and Boann Social Impact, as well as the Northpine Foundation, which was established by John Phillips, an early Shopify backer, and his wife Cathy. According to Peter van der Velden, executive chairman of Lumira Ventures, the fund expects to complete its fundraising and close its initial tranche soon.
The investment strategy allocates at least 25% of fund proceeds to early-stage cancer treatment developers, with remaining capital deployed through co-investment arrangements alongside Lumira's separate life sciences fund, which is currently raising US$200 million for Canadian and U.S. life sciences companies. The larger Lumira fund targets 40% of its total allocation to cancer-focused companies. The Cancer Breakthrough Fund is structured to make approximately 13 total investments across both early and more advanced development stages.
This philanthropic venture capital model mirrors successful precedents in the U.S., including the Cystic Fibrosis Foundation's venture initiatives, the American Cancer Society's BrightEdge fund, and the Juvenile Diabetes Research Foundation's T1D fund. The approach represents an evolution in how major disease-focused nonprofits are mobilizing capital to accelerate commercial development of breakthrough treatments, combining nonprofit mission focus with venture capital's operational and financial discipline.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.